Potential Drug-Drug Interactions in Critically Ill Medical Patients: A Cross-Sectional Study

Keywords: Keywords: critically ill, drug-drug interaction, interaction compendia, potential drug interactions, prevalence,

Abstract

ABSTRACT Background:  Drug interaction commonly occurred in critically ill patients and may increase hospital lengths of stay and total cost. The aim of the present study is to evaluate potential drug-drug interaction in critically ill patients. Methods: In this cross-sectional study, medical records of critically ill patients admitted to the 16-bed intensive-care units of a teaching hospital were assessed according to the Micromedex® drug interaction and drug interaction fact®. The identified drug-drug interactions were categorized by level of severity. The agreement between two resources was assessed. Results: Our survey found 915 and 564 paired DDIs according to the Micromedex® and drug interaction fact®, respectively, amongst 120 patients.  The prevalence of potential DDIs (pDDIs) was 87.7% and 91.7% with drug interaction Fact® and Micromedex®, respectively. Approximately, 80% of recruited patients, had at least three pDDIs based on Micromedex®. A significant moderate agreement between two drug interaction compendia was reported. (kappa= 0.41, 95% CI: 0.167-0.649, p<0.001). The serotonin syndrome, increasing the risk of bleeding and hyperkalemia were the major possible consequence of potential DDIs; but none of them occurred. Conclusions: Most of the observed interactions were mild to moderate in nature. However, major and contraindicated interactions are possible in critically ill patients. Therefore, monitoring of patients with possible major or contraindicated drug interaction is recommended. Abbreviations: ICU: intensive care unit, DDI: drug-drug interactions (DDIs), pDDI: potential drug-drug interactions

References

REFERENCES:
1 Vonbach P, Dubied A, Krähenbühl S, Beer JH. Prevalence of drug–drug interactions at hospital entry and during hospital stay of patients in internal medicine. Eur J Intern Med. 2008;19(6):413-20.
2 Moura C, Prado N, Acurcio F. Potential drug-drug interactions associated with prolonged stays in the intensive care unit. Clin Drug Investig. 2011;31(5):309-16.
3 van den Bemt PM, Egberts TC, Brouwers JR. Drug-related problems in hospitalised patients. Drug Saf. 2000;22(4):321-33.
4 Glintborg B, Andersen SE, Dalhoff K. Drug-drug interactions among recently hospitalised patients–frequent but mostly clinically insignificant. Eur J Clin Pharmacol. 2005;61(9):675-81.
5 Obreli-Neto PR, Nobili A, de Oliveira Baldoni A, Guidoni CM, de Lyra Júnior DP, Pilger D, et al. Adverse drug reactions caused by drug–drug interactions in elderly outpatients: a prospective cohort study. Eur J Clin Pharmacol. 2012;68(12):1667-76.
6 Uijtendaal EV, Harssel LL, Hugenholtz GW, Kuck EM, Zwart‐van Rijkom JE, Cremer OL, et al. Analysis of Potential Drug‐Drug Interactions in Medical Intensive Care Unit Patients. Pharmacotherapy.2014;34(3):213-9.
7 Barrons R. Evaluation of personal digital assistant software for drug interactions. American journal of health-system pharmacy. 2004;61(4):380-5.
8 Hasanloei V, Amin M, Hamdolah S, Aysa H. Drug–drug interactions prevalence in intensive care unit patients of a university hospital in Iran. BEPLS. 2014;3:87-91.
9 Roblek T, Vaupotic T, Mrhar A, Lainscak M. Drug-drug interaction software in clinical practice: a systematic review. European journal of clinical pharmacology. 2015;71(2):131-42.
10 Patel RI, Beckett RD. Evaluation of resources for analyzing drug interactions. JMLA. 2016;104(4):290.
11 Janković SM, Pejčić AV, Milosavljević MN, Opančina VD, Pešić NV, Nedeljković TT, et al. Risk factors for potential drug-drug interactions in intensive care unit patients. J Crit Care. 2018;43:1-6.
12 El Samia Mohamed S, Gad Z, El-Nimr N, Abdel Razek A. Prevalence and Pattern of Potential Drug-Drug Interactions in the Critical Care Units of a Tertiary Hospital in Alexandria, Egypt. Adv Pharmacoepidemiol Drug Saf. 2013;2:144.
13 Vanham D, Spinewine A, Hantson P, Wittebole X, Wouters D, Sneyers B. Drug-drug interactions in the intensive care unit: Do they really matter? J Crit Care. 2017;38:97-103.
14 Lima REF, Cassiani SHDB. Potential drug interactions in intensive care patients at a teaching hospital. Rev Lat Am Enfermagem. 2009;17(2):222-7.
15 Uijtendaal EV, van Harssel LL, Hugenholtz GW, Kuck EM, Zwart‐van Rijkom JE, Cremer OL, et al. Analysis of potential drug‐drug interactions in medical intensive care unit patients. Pharmacotherapy. 2014;34(3):213-9.
16 Hammes JA, Pfuetzenreiter F, Silveira Fd, Koenig Á, Westphal GA. Potential drug interactions prevalence in intensive care units. Rev Bras Ter Intensiva. 2008;20(4):349-54.
17 Ayvaz S, Horn J, Hassanzadeh O, Zhu Q, Stan J, Tatonetti NP, et al. Toward a complete dataset of drug–drug interaction information from publicly available sources. J Biomed Inform. 2015;55:206-17.
18 Rafiei H, Abdar ME, Amiri M, Ahmadinejad M. The study of harmful and beneficial drug interactions in intensive care, Kerman, Iran. JICS. 2013;14(2):155-8.
19 Abideen S, Vivekanandan K, Mishra P. Assessment of prevalence of potential drug-drug interactions in medical intensive care unit of a tertiary care hospital in India. ASMNT. 2015;8(1).
20 Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46-e110.
21 Cruciol-Souza JM, Thomson JC. Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital. J Pharm Pharm Sci. 2006 Jan;9(3):427-33.
Published
2019-07-16
How to Cite
1.
Hosseini E, Shojaei L, Karimpour H, Shahbazi F. Potential Drug-Drug Interactions in Critically Ill Medical Patients: A Cross-Sectional Study. J Pharm Care. 6(3-4):52-57.
Section
Original Article(s)